{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:08:03Z","timestamp":1781910483389,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10067-026-07932-3","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:38:30Z","timestamp":1768966710000},"page":"1657-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimizing missed latent tuberculosis infection under adalimumab: real-world data from a BCG-vaccinated cohort"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-0168","authenticated-orcid":false,"given":"Fatma Merve","family":"Ko\u00e7ak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-6178","authenticated-orcid":false,"given":"Berru","family":"Yarg\u0131 \u00d6zko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"7932_CR1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/nejmoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104. https:\/\/doi.org\/10.1056\/nejmoa011110","journal-title":"N Engl J Med"},{"key":"7932_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:1185\u20131206. https:\/\/doi.org\/10.1183\/09031936.00028510","journal-title":"Eur Respir J"},{"key":"7932_CR3","unstructured":"T\u00fcrkiye Cumhuriyeti Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131. T\u00fcberk\u00fcloz Tan\u0131 ve Tedavi Rehberi. Ankara: 2019 (Yay\u0131n No:1129)"},{"key":"7932_CR4","unstructured":"World Health Organization. Latent Tuberculosis Infection: Updated and consolidated guidelines for programmatic management. Geneva 2018."},{"key":"7932_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ARD-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L et al (2023) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 82:742\u2013753. https:\/\/doi.org\/10.1136\/ARD-2022-223335","journal-title":"Ann Rheum Dis"},{"key":"7932_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/S00296-021-04926-z","volume":"42","author":"A Hacioglu","year":"2022","unstructured":"Hacioglu A, Borekci S, Melikoglu M, Ozguler Y, Esatoglu SN, Ugurlu S et al (2022) Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. Rheumatol Int 42:1443\u20131451. https:\/\/doi.org\/10.1007\/S00296-021-04926-z","journal-title":"Rheumatol Int"},{"key":"7932_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","volume":"14","author":"G Murdaca","year":"2015","unstructured":"Murdaca G, Span\u00f2 F, Contatore M, Guastalla A, Penza E, Magnani O et al (2015) Infection risk associated with anti-TNF-\u03b1 agents: a review. Expert Opin Drug Saf 14:571\u2013582. https:\/\/doi.org\/10.1517\/14740338.2015.1009036","journal-title":"Expert Opin Drug Saf"},{"key":"7932_CR8","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1007\/S10067-021-05697-5","volume":"40","author":"Y Kaptan","year":"2021","unstructured":"Kaptan Y, Suner A, Ta\u015f MN, Oksel F, Aksu K, Sayiner A (2021) Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy. Clin Rheumatol 40:3783\u20133788. https:\/\/doi.org\/10.1007\/S10067-021-05697-5","journal-title":"Clin Rheumatol"},{"key":"7932_CR9","doi-asserted-by":"publisher","unstructured":"Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A et al (2020) Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 69(1):1\u201311. https:\/\/doi.org\/10.15585\/MMWR.RR6901A1","DOI":"10.15585\/MMWR.RR6901A1"},{"key":"7932_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/09273948.2020.1834588","volume":"30","author":"I Hernanz","year":"2022","unstructured":"Hernanz I, Miguel Escuder L, Chamorro L, Moll-Udina A, Espinosa G, de la Sainz Maza M et al (2022) Tuberculosis-related uveitis in patients under anti-TNF-alpha therapy: a case series. Ocul Immunol Inflamm 30:839\u201344. https:\/\/doi.org\/10.1080\/09273948.2020.1834588","journal-title":"Ocul Immunol Inflamm"},{"key":"7932_CR11","unstructured":"Global tuberculosis report (2023) Geneva: world health organization. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2023. Accessed 28 Sept 2025"},{"key":"7932_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ G\u00f3mez-Reino","year":"2007","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Descalzo M\u00c1 (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756\u2013761. https:\/\/doi.org\/10.1002\/art.22768","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"7932_CR13","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/J.CMI.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley JW, Cantini F, Goletti D, G\u00f3mez-Reino JJ, Mylonakis E, San-Juan R et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin Microbiol Infect 24(Suppl 2):S10-20. https:\/\/doi.org\/10.1016\/J.CMI.2017.12.025","journal-title":"Clin Microbiol Infect"},{"key":"7932_CR14","doi-asserted-by":"publisher","unstructured":"Dobler CC (2016) Biologic agents and tuberculosis. Microbiol Spectr 4(6).\u00a0https:\/\/doi.org\/10.1128\/MICROBIOLSPEC.TNMI7-0026-2016","DOI":"10.1128\/MICROBIOLSPEC.TNMI7-0026-2016"},{"key":"7932_CR15","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/ART.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, C\u00f6ster L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52:1986\u20131992. https:\/\/doi.org\/10.1002\/ART.21137","journal-title":"Arthritis Rheum"},{"key":"7932_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1756-185X.12708","volume":"19","author":"F Cantini","year":"2016","unstructured":"Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C et al (2016) Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Int J Rheum Dis 19:799\u2013805. https:\/\/doi.org\/10.1111\/1756-185X.12708","journal-title":"Int J Rheum Dis"},{"key":"7932_CR17","doi-asserted-by":"publisher","unstructured":"Kedia S, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G et al (2020) Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol 115:340\u2013349. https:\/\/doi.org\/10.14309\/AJG.0000000000000527","DOI":"10.14309\/AJG.0000000000000527"},{"key":"7932_CR18","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3748\/WJG.V21.I11.3308","volume":"21","author":"ES Kim","year":"2015","unstructured":"Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI et al (2015) Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol 21:3308\u20133316. https:\/\/doi.org\/10.3748\/WJG.V21.I11.3308","journal-title":"World J Gastroenterol"},{"key":"7932_CR19","doi-asserted-by":"publisher","unstructured":"de Melo Lima L, Aurilio RB, Fonseca AR, Parente AAAI, de F\u00e1tima Bazhuni Pombo Sant\u2019Anna M, Sant\u2019Anna CC (2023) Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review. Revista Paulista de Pediatria 42:e2022084.\u00a0https:\/\/doi.org\/10.1590\/1984-0462\/2024\/42\/2022084","DOI":"10.1590\/1984-0462\/2024\/42\/2022084"},{"key":"7932_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/JRHEUM.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40:74\u201379. https:\/\/doi.org\/10.3899\/JRHEUM.120583","journal-title":"J Rheumatol"},{"key":"7932_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.AJO.2022.03.017","volume":"240","author":"LEM Eurelings","year":"2022","unstructured":"Eurelings LEM, Missotten TOAR, van Velthoven MEJ, van Daele PLA, van Laar JAM, van Hagen PM et al (2022) Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy. Am J Ophthalmol 240:194\u2013204. https:\/\/doi.org\/10.1016\/J.AJO.2022.03.017","journal-title":"Am J Ophthalmol"},{"key":"7932_CR22","doi-asserted-by":"publisher","unstructured":"Ramiro S, Landew\u00e9 R, Van Der Heijde D, Harrison D, Collier D, Michaud K (2015) Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open 1(1):e000155.\u00a0https:\/\/doi.org\/10.1136\/RMDOPEN-2015-000155","DOI":"10.1136\/RMDOPEN-2015-000155"},{"key":"7932_CR23","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/S00296-011-2030-8","volume":"32","author":"O Kilic","year":"2012","unstructured":"Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N (2012) Is it safe to use anti-TNF-\u03b1 agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 32:2675\u20132679. https:\/\/doi.org\/10.1007\/S00296-011-2030-8","journal-title":"Rheumatol Int"},{"key":"7932_CR24","doi-asserted-by":"publisher","unstructured":"Parigi S, Licari A, Manti S, Marseglia GL, Tosca MA, Del Giudice MM et al (2020) Tuberculosis and TNF-\u03b1 inhibitors in children: how to manage a fine balance. Acta Biomed 91(11\u2013S):e2020009. https:\/\/doi.org\/10.23750\/ABM.V91I11-S.10311","DOI":"10.23750\/ABM.V91I11-S.10311"},{"key":"7932_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5588\/IJTLD.13.0644","volume":"18","author":"YJ Jung","year":"2014","unstructured":"Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG et al (2014) The \u201ceither test positive\u201d strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 18:428\u2013434. https:\/\/doi.org\/10.5588\/IJTLD.13.0644","journal-title":"Int J Tuberc Lung Dis"},{"key":"7932_CR26","unstructured":"Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection --- United States, 2010 (2010) MMWR Recommendations and Reports 59(RR-5):1\u201325.\u00a0https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5905a1.htm. Accessed 15 Oct 2025"},{"key":"7932_CR27","doi-asserted-by":"publisher","unstructured":"Pai M, Zwerling A, Menzies D (2008) Systematic review: t-cell\u2013based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177\u2013184. https:\/\/doi.org\/10.7326\/0003-4819-149-3-200808050-00241","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"7932_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/IBD.21427","volume":"17","author":"P Papay","year":"2011","unstructured":"Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W et al (2011) Factors impacting the results of interferon-\u03b3 release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 17:84\u201390. https:\/\/doi.org\/10.1002\/IBD.21427","journal-title":"Inflamm Bowel Dis"},{"key":"7932_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/J.SEMARTHRIT.2012.07.001","volume":"42","author":"JH Kim","year":"2013","unstructured":"Kim JH, Cho SK, Han M, Choi CB, Kim TH, Jun JB et al (2013) Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum 42:424\u2013432. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2012.07.001","journal-title":"Semin Arthritis Rheum"},{"key":"7932_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1513\/ANNALSATS.201608-647OC","volume":"14","author":"J Lee","year":"2017","unstructured":"Lee J, Kim E, Jang EJ, Lee CH, Lee EY, Im JP et al (2017) Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist. Ann Am Thorac Soc 14:690\u2013697. https:\/\/doi.org\/10.1513\/ANNALSATS.201608-647OC","journal-title":"Ann Am Thorac Soc"},{"key":"7932_CR31","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/ART.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766\u20131772. https:\/\/doi.org\/10.1002\/ART.21043","journal-title":"Arthritis Rheum"},{"key":"7932_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCTUBE.2024.100460","volume":"36","author":"T Maeda","year":"2024","unstructured":"Maeda T, Connolly M, Thevenet-Morrison K, Levy P, Utell M, Munsiff S et al (2024) Tuberculosis screening for patients on biologic medications: a single-center experience and society guideline review, Monroe County, New York, 2018\u20132021. J Clin Tuberc Other Mycobact Dis 36:100460. https:\/\/doi.org\/10.1016\/J.JCTUBE.2024.100460","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"7932_CR33","unstructured":"Chapter of Rheumatologists, College of Physicians, Academy of Medicine, Singapore (2025) Consensus statement on testing for latent tuberculosis in people with rheumatic disease. Singapore"},{"key":"7932_CR34","doi-asserted-by":"publisher","DOI":"10.21037\/ATM.2021.AB008","volume":"9","author":"U Khanna","year":"2021","unstructured":"Khanna U, Ellis A, Gallop J, Galadari A, Hu J, Fernandez AP (2021) AB008. Utility of repeat latent tuberculosis testing in patients with immune-mediated diseases taking biologics. Ann Transl Med 9:AB008. https:\/\/doi.org\/10.21037\/ATM.2021.AB008","journal-title":"Ann Transl Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07932-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:32Z","timestamp":1771581212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07932-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7932"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07932-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Ethics Committee of the University of Health Sciences, Istanbul Training and Research Hospital (Approval number: 135, Date: 30.05.2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for informed consent was waived by the ethics committee due to the retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The research was conducted in accordance with the Declaration of Helsinki and institutional ethical guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}